A Novel Protein Glycan Biomarker and Future Cardiovascular Disease Events
A Novel Protein Glycan Biomarker and Future Cardiovascular Disease Events
复制标题
DOI：
10.1161/jaha.114.001221
复制
发表时间：
2014-10-01
影响因子：
5.4
通讯作者：
Mora, Samia
中科院分区：
文献类型：
--
作者：
Akinkuolie, Akintunde O.;Buring, Julie E.;Mora, Samia
糖基化蛋白参与包括炎症在内的多种细胞过程。我们假设，GlycA，一种新的生物标志物的蛋白聚糖N-乙酰基组，是相关的事件心血管疾病（CVD），我们比较了它与高敏C反应蛋白（hsCRP）。方法和结果，在27 491最初健康的妇女，基线GlycA量化的核磁共振光谱和hsCRP的免疫比浊法测定。在17.2年的中位随访期间，发生了1648起CVD事件（心肌梗死、缺血性卒中、冠状动脉血运重建和CVD死亡）。GlycA与hsCRP中度相关（斯皮尔曼r=0.61，P
Background-Glycosylated proteins partake in multiple cellular processes including inflammation. We hypothesized that GlycA, a novel biomarker of protein glycan N-acetyl groups, is related to incident cardiovascular disease (CVD), and we compared it with high-sensitivity C-reactive protein (hsCRP).Methods and Results-In 27 491 initially healthy women, baseline GlycA was quantified by nuclear magnetic resonance spectroscopy and hsCRP by an immunoturbidimetric assay. During median follow-up of 17.2 years, 1648 incident CVD events occurred (myocardial infarction, ischemic stroke, coronary revascularization, and CVD death). GlycA and hsCRP were moderately correlated (Spearman r=0.61, P